

July 23, 2026

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Subject: Outcome of the Board Meeting held on Thursday, July 23, 2026

- 1) Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the quarter ended June 30, 2026; and
- 2) Re-Appointment of Internal Auditor for the Financial Year 2026-27

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), we wish to inform you that the Board of Directors of the Company ("**Board**"), at its meeting held today, i.e., **Thursday, July 23, 2026**, inter alia, considered and approved the following matters:

1. Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the quarter ended June 30, 2026

The Board has approved the Unaudited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the quarter ended June 30, 2026.

Pursuant to Regulation 33(3) of the SEBI Listing Regulations, copies of the Standalone and Consolidated unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Reports on the said financial results issued by the Statutory Auditors of the Company are attached as an **Annexure A** to this letter.

2. Re-Appointment of Internal Auditor for the Financial Year 2026-27

Based on the recommendation of the Audit Committee, the Board has approved the re-appointment of **M/s. Ernst & Young LLP, Chartered Accountants**, as Internal Auditors of the Company for the Financial Year 2026-27.

Disclosure of information pursuant to Regulation 30 of SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed as **Annexure B** to this letter.

The above disclosures are also being made available on the website of the Company at <https://investor.thyrocare.com>.

The Board Meeting commenced at 2:45 P.M. and concluded at 03:35 P.M.

This is for your information and records.

Yours Faithfully,
For **Thyrocare Technologies Limited**,



Brijesh Kumar
Company Secretary and Compliance Officer
Encl. A/a

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Thyrocare Technologies Limited
D-3711, MIDC, Turbhe, Opp. Sandoz,
Navi Mumbai - 400 703.

1. We have reviewed the unaudited standalone financial results of Thyrocare Technologies Limited (the "Company") for the quarter ended June 30, 2026, which are included in the accompanying 'Unaudited Standalone Financial Results for the Quarter ended June 30, 2026' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Price Waterhouse Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West), Mumbai - 400 028
T: +91(22) 66697510

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its Conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

5. (a) The standalone financial results of the Company for the quarter ended June 30, 2025 were reviewed by another firm of chartered accountants who issued their unmodified conclusion, vide their report dated July 23, 2025.
- (b) The standalone financial statements of the Company for the year ended March 31, 2026 were audited by another firm of Chartered Accountants, who issued an unmodified opinion vide their report dated May 07, 2026.

Our conclusion is not modified in respect of these matters.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Nitin Khatri
Partner
Membership Number: 110282

UDIN: 26110282PLRUZK1897
Place: Mumbai
Date: July 23, 2026.

THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: kumar.brijesh@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882

Unaudited Standalone Financial Results for the Quarter ended June 30, 2026

Sr. No	Particulars	Quarter ended			(Rs. in Crores)
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
			Refer Note 2		
1	Revenue				
(a)	Revenue from operations	225.66	210.67	178.89	774.27
(b)	Other Income	3.51	3.72	3.96	13.39
	Total Reveue (a+b)	229.17	214.39	182.85	787.66
2	Expenses				
(a)	Cost of materials consumed	58.86	54.27	52.37	208.37
(b)	Purchase of stock-in-trade	0.03	0.77	0.07	1.09
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.24	(0.51)	0.15	(0.23)
(d)	Employee benefits expense	37.16	33.44	30.70	128.29
(e)	Finance cost	1.26	1.43	0.62	2.18
(f)	Depreciation and amortisation expense	11.23	12.94	8.95	51.17
(g)	Other expenses	53.76	50.07	39.08	180.42
	Total Expenses	162.54	152.41	131.94	571.29
3	Profit before exceptional items and income tax (1 - 2)	66.63	61.98	50.91	216.37
4	Exceptional Items	-	-	-	5.97
5	Profit after exceptional items and before tax (3 - 4)	66.63	61.98	50.91	210.40
6	Tax expense	(16.46)	(18.40)	(14.86)	(61.59)
7	Profit for the period/year (5 + 6)	50.17	43.58	36.05	148.81
8	Other comprehensive income				
	Items that will not be reclassified to profit or loss (net of tax)	0.48	0.48	(0.21)	0.22
9	Total comprehensive income for the period/ year (7 + 8)	50.65	44.06	35.84	149.03
	Paid-up equity share capital (Face value of Rs. 10/- each)	159.17	159.17	52.99	159.17
	Other equity				401.51
10	Earnings per share (of Rs. 10/- each):				
(a)	Basic (in Rs.)	3.15*	2.75*	2.27*	9.36
(b)	Diluted (in Rs.)	3.14*	2.75*	2.26*	9.34
	*not annualised				
	See accompanying notes to the Standalone Financial Results				

Notes :

- The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 23 July 2026 and subsequently approved by the Board of Directors at its meeting held on 23 July 2026. The statutory auditors of the Company have expressed an unmodified conclusion on the standalone unaudited financial results for the quarter ended 30 June 2026.
- The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarter ended 31 December 2025.
- These unaudited standalone financial results have been prepared in compliance with the recognition and remasurement principles of Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.



THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: kumar.brijesh@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882

- 4 During the quarter ended 30 June 2026, the Company has forfeited 3,733 equity stock options and no equity stock options respectively granted to employees under Employee Stock Option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable.
- 5 In accordance with Ind AS 108 'Operating Segments', segment information has been given in the unaudited consolidated financial results of the Group.
- 6 The earning per share in respect of quarter ended 30 June 2025 has been restated considering the allotment of bonus shares and adjustment in respect of outstanding stock options, in line with the requirements of Ind AS 33 "Earnings Per Share".
- 7 The unaudited standalone financial results are available on the website of the Company (www.thyrocare.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).



For and on behalf of Board of Directors

Rahul Guha
Managing Director

DIN - 09588432

Navi Mumbai, 23 July 2026

Price Waterhouse Chartered Accountants LLP

Review Report

To

The Board of Directors

Thyrocare Technologies Limited

D-3711, MIDC, Turbhe, Opp. Sandoz,

Navi Mumbai - 400 703.

1. We have reviewed the unaudited consolidated financial results of Thyrocare Technologies Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries hereinafter referred to as the "Group"), and its share of the net profit after tax and total comprehensive income of its associate company for the quarter ended June 30, 2026 which are included in the accompanying 'Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026' (the "Statement"). The Statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialed by us for identification purposes.
2. This Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

- Thyrocare Technologies Limited (Holding Company)
- Nuclear Healthcare Limited (Subsidiary)
- Pulse Hitech Health Services (Ghatkopar) LLP (Subsidiary)
- Think Health Diagnostic Private Limited (Subsidiary)
- Thyrocare Laboratories (Tanzania) Limited (Subsidiary)
- Equinox Labs Private Limited (Associate)



Price Waterhouse Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West), Mumbai - 400 028
T: +91(22) 66697510

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its Conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results include the interim financial results of three subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 3.20 Crores and total comprehensive loss of Rs. 0.84 Crores for the quarter ended June 30, 2026, as considered in the unaudited consolidated financial results. The unaudited consolidated financial results also include the Group's share of total comprehensive income of Rs. 0.71 Crores for the quarter ended June 30, 2026, as considered in the unaudited consolidated financial results, in respect of one associate based on their interim financial results, which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

7. (a) The comparative figures of the Group as set out in the Statement for the quarter ended June 30, 2025 were reviewed by another firm of Chartered Accountants who, vide their report dated July 23, 2025 expressed an unmodified conclusion on the same.

(b) The consolidated financial statements of the Company for the year ended March 31, 2026, were audited by another firm of chartered accountants under the Companies Act, 2013 who, vide their report dated May 07, 2026, expressed an unmodified opinion on those financial statements.

Our conclusion on the Statement is not modified in respect of the above matters.

For Price Waterhouse Chartered Accountants LLP

Firm Registration Number: 012754N/N500016



Nitin Khatri

Partner

Membership Number : 110282

UDIN : 26110282YDUQIA7954

Place: Mumbai

Date: July 23, 2026

THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: kumar.brijesh@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882

Unaudited Consolidated Financial Results for the Quarter ended June 30, 2026

(Rs. in Crores)

Sr. No	Particulars	Quarter ended			Year ended
		June 30, 2026 (Unaudited)	March 31, 2026 (Unaudited) Refer Note 3	June 30, 2025 (Unaudited)	March 31, 2026 (Audited)
1	Revenue				
(a)	Revenue from operations	240.02	223.95	193.03	829.04
(b)	Other Income	4.15	4.31	4.65	16.99
	Total Revenue (a+b)	244.17	228.26	197.68	846.03
2	Expenses				
(a)	Cost of materials consumed	61.88	56.42	55.41	218.71
(b)	Purchase of stock-in-trade	0.03	0.77	0.07	1.09
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.25	(0.51)	0.15	(0.23)
(d)	Employee benefits expense	39.61	36.07	33.00	138.06
(e)	Finance cost	1.35	1.52	0.78	2.80
(f)	Depreciation and amortisation expense	12.49	14.03	11.41	58.58
(g)	Other expenses	60.98	56.11	46.63	209.37
	Total Expenses	176.59	164.41	147.45	628.38
3	Profit before exceptional items, share of profit of associate and income tax (1 - 2)	67.58	63.85	50.23	217.65
4	Exceptional Items	-	-	-	6.16
5	Profit before share of profit of associate and income tax (3-4)	67.58	63.85	50.23	211.49
6	Share of profit of associate	0.71	0.58	0.25	1.39
7	Profit before tax (5-6)	68.29	64.43	50.48	212.88
8	Tax expense	(16.96)	(15.73)	(12.19)	(50.03)
9	Profit for the period/year (7 + 8)	51.33	48.70	38.29	162.85
10	Other comprehensive income				
(a)	Items that will not be reclassified to profit or loss (net of tax)	0.39	0.66	(0.23)	0.38
11	Total comprehensive income for the period/ year (9+10)	51.72	49.36	38.06	163.23
12	Profit/ (Loss) attributable to :				
(a)	Owners of the company	52.19	47.11	38.93	163.04
(b)	Non-controlling interest	(0.86)	1.59	(0.64)	(0.19)
		51.33	48.70	38.29	162.85
13	Total comprehensive income attributable to :				
(a)	Owners of the company	52.58	47.77	38.70	163.42
(b)	Non-controlling interest	(0.86)	1.59	(0.64)	(0.19)
		51.72	49.36	38.06	163.23
	Paid-up equity share capital (Face value of Rs. 10/- each)	159.17	159.17	52.99	159.17
	Other equity				426.33
14	Earnings per share (of Rs. 10/- each):				
(a)	Basic (in Rs.)	3.23*	2.99*	2.41*	10.27
(b)	Diluted (in Rs.)	3.22*	2.98*	2.40*	10.24
	*not annualised				
	See accompanying notes to the Consolidated Financial Results				



For and on behalf of Board of Directors



Rahul Guha
Managing Director
DIN - 09588432
Navi Mumbai, 23 July 2026

THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: kumar.brijesh@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882

Notes:

- Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker evaluates the Group's Performance. The Group has identified business segments as its primary segments. The Group recognizes its diagnostic testing services activity and imaging services including manufacturing of radiopharmaceuticals activity as its primary business segments. Diagnostic testing services operations predominantly consists of providing laboratory testing services to its customers. Imaging services segment represents PET-CT scan and sale of radio pharmaceuticals used in imaging services. Others represents trading and other related business activities. The accounting principles used in the preparation of the financial statements are consistently applied to record revenue and expenditure in individual segments.

(Rs. in Crores)

Particulars	Quarter ended			Year ended 31 March 2026 (Audited)
	June 30, 2026 (Unaudited)	March 31, 2026 (Unaudited) Refer Note 3	June 30, 2025 (Unaudited)	
Segment Revenue				
Diagnostic Testing Services	226.21	210.22	178.33	772.53
Imaging Services	13.48	12.48	14.04	53.14
Others	0.33	1.25	0.66	3.37
Total	240.02	223.95	193.03	829.04
Less : Intersegment Revenue	-	-	-	-
Revenue from Operations	240.02	223.95	193.03	829.04
Segment Results before tax, exceptional items, share of profit/loss of associate and jointly controlled entity and income tax				
Diagnostic Testing Services	61.90	58.86	44.85	197.48
Imaging Services	1.26	(0.30)	0.27	0.67
Others	0.27	0.98	0.46	2.51
Total	63.43	59.54	45.58	200.66
Add : Unallocable income net off other unallocable expenditure	4.15	4.31	4.65	16.99
Total Profit before exceptional items, share of profit/loss of associate and jointly controlled entity and income tax	67.58	63.85	50.23	217.65
Exceptional items	-	-	-	(6.16)
Share of profit/ (loss) of associate and jointly controlled entity	0.71	0.58	0.25	1.39
Profit before tax	68.29	64.43	50.48	212.88
Segment assets				
Diagnostic Testing Services	586.12	514.08	518.32	514.08
Imaging Services	203.94	192.34	184.58	192.34
Others	-	-	-	-
Unallocated	43.04	40.80	34.70	40.80
	833.10	747.22	737.60	747.22
Segment Liabilities				
Diagnostic Testing Services	175.89	147.35	121.12	147.35
Imaging Services	11.87	11.47	14.61	11.47
Others	-	-	-	-
Unallocated	2.38	2.38	9.18	2.38
	190.14	161.20	144.91	161.20

- The above unaudited consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 23 July 2026 and subsequently approved by the Board of Directors at its meeting held on 23 July 2026. The statutory auditors of the Holding company have expressed an unmodified conclusion on the consolidated unaudited financial results for the quarter ended 30 June 2026.
- The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of the full financial year and the limited reviewed year to date figures up to the quarters ended 31 December 2025.
- These unaudited consolidated financial results have been prepared in compliance with the recognition and remasurement principles of Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.



THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: kumar.brijesh@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882

- 5 During the quarter ended 30 June 2026, the Holding Company has forfeited 3,733 equity stock options and no equity stock options respectively granted to employees under Employee Stock Option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable.
- 6 The earning per share in respect of quarter ended 30 June 2025 has been restated considering the allotment of bonus shares and adjustment in respect of outstanding stock options, in line with the requirements of Ind AS 33 "Earnings Per Share".
- 7 The unaudited consolidated financial results are available on the website of the Company (www.thyrocare.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).

For and on behalf of Board of Directors



Rahul Guha
Managing Director
DIN - 09588432

Navi Mumbai, 23 July 2026

Disclosure of information pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Re-appointment of Internal Auditor of the Company

1.	Name of Internal Auditor	M/s. Ernst & Young LLP, Chartered Accountants ("EY")
2.	Reason for change viz. appointment , re-appointment, resignation , removal, death or otherwise	Re-appointment
3.	Date of appointment /re-appointment/ cessation (as applicable) & term of appointment /re-appointment;	Date of Re-appointment: July 23, 2026 Term of Appointment: For the Financial year 2026-27
4.	Brief Profile (in case of appointment)	EY India is a globally connected, multidisciplinary professional services organization driven by the purpose of "Shaping the future with confidence" for its clients, people and communities. Through its four service lines - Assurance, Consulting, Tax, and Strategy and Transactions and its deep sector knowledge, EY India helps its clients capitalize on new opportunities, assess and manage risks, deliver responsible growth, fulfil regulatory requirements, keep investors informed, and meet stakeholder needs. EY India has a workforce of over 48,000 professionals with a presence across 16 cities in India, including Ahmedabad, Bengaluru, Bhubaneswar, Chandigarh, Chennai, Gandhinagar, Hyderabad, Jaipur, Kochi, Kolkata, Mumbai, NCR (New Delhi, Gurugram and Noida), Pune and Vadodara. EY India's Risk Consulting services assist clients in transforming their risk and control functions while building confidence among stakeholders.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable